Loading...

Loading...

Pfizer’s BRAFTOVI Regimen Approved for Metastatic CRC
Pfizer’s BRAFTOVI Regimen Approved for Metastatic CRC
By MBN Staff - Mon, 12/23/2024 - 13:39
Pfizer's BRAFTOVI, combined with cetuximab and mFOLFOX6, is FDA-approved for treating metastatic colorectal cancer with a BRAF V600E mutation.

Featured content

Most popular

Partnership Content

Cluster Automotriz Nuevo Leon
https://mexicobusiness.news/tag/treatment-options
More Health
FDA Approves Miplyffa for Niemann-Pick Disease Type C
FDA Approves Miplyffa for Niemann-Pick Disease Type C
By MBN Staff - Tue, 09/24/2024 - 11:17
FDA approves Zevra's MIPLYFFA for Niemann-Pick disease C, offering hope for patients with this rare, fatal condition.